Garth is a medical graduate who undertook post-graduate training in General Medicine and Clinical Pharmacology at the Universities of Glasgow and Oxford. He joined Pfizer Central Research in 1988 and was involved in the early development of range of new compounds. After moving to GSK he was head of the Respiratory Centre of Excellence for Drug Discovery (CEDD) leading to the development of new long acting inhaled therapies for COPD and asthma.Garth Rapeport is CEO of Pulmocide Ltd ,a drug discovery company working on the identification of new treatments for Invasive Aspergillosis and RSV and visiting Professor at the National Heart & Lung Institute, Imperial College School of Medicine in London.
Pulmonary diseases